A fusion protein will be expressed which includes ubiquitin plus the protein of interest.

According to the present invention, the expressed fusion protein targets the vacuole and the target protein of the fusion protein is expressed at the surface of the vacuole.

A fusion protein which comprises MGF and IL-3.

The fusion protein optionally comprises a linker.

  Also disclosed is a fusion protein.

The fusion protein can be used as a vaccine.

A co-protein such as GST or β-galactosidase may be attached to the amino terminus of the fused protein, such as to stabilise and solubilise the fused protein.

A fusion protein comprises of a therapeutic polypeptide and a scaffold protein.

It further relates to a fusion protein to be used in said method and a nucleic acid encoding said fusion protein.

The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.

The protein may be a full-length native or recombinant N. caninum or Toxoplasma gondii bradyzoite fusion protein or a truncated fusion protein or fragment thereof.

The invention further refers to nucleic acids encoding the inventive fusion protein and to expression vectors, comprising the inventive fusion protein and additionally the protein of interest (POI).

A fusion gene coding the said fusion protein, a express vector containing this fusion gene and a method using methylotrophic yeast to express the secretory recombination fusion protein are disclosed too.

The invention is directed to methods of producing a fusion protein by administering a nucleic acid encoding the fusion protein to an animal.

The expressed target fusion protein contains a DNA-binding domain and a target protein.